Geode Capital Management LLC Has $32.10 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Geode Capital Management LLC boosted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,842,301 shares of the company's stock after acquiring an additional 111,256 shares during the quarter. Geode Capital Management LLC owned about 2.36% of Travere Therapeutics worth $32,100,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in shares of Travere Therapeutics by 2.2% in the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company's stock worth $2,112,000 after purchasing an additional 2,640 shares in the last quarter. Arizona State Retirement System grew its position in Travere Therapeutics by 13.5% in the fourth quarter. Arizona State Retirement System now owns 22,396 shares of the company's stock worth $390,000 after buying an additional 2,666 shares during the last quarter. R Squared Ltd bought a new position in shares of Travere Therapeutics in the fourth quarter valued at $53,000. Diversified Trust Co lifted its position in shares of Travere Therapeutics by 27.5% during the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company's stock valued at $256,000 after acquiring an additional 3,169 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Travere Therapeutics by 23.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,206 shares of the company's stock valued at $317,000 after acquiring an additional 3,494 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TVTX shares. Guggenheim reaffirmed a "buy" rating and set a $47.00 target price on shares of Travere Therapeutics in a research report on Monday, April 14th. HC Wainwright lifted their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, January 15th. Bank of America boosted their price target on Travere Therapeutics from $29.00 to $31.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Citigroup increased their target price on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a research report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $32.08.

Travere Therapeutics Stock Performance

Travere Therapeutics stock traded up $0.77 on Tuesday, hitting $15.88. The company's stock had a trading volume of 1,277,972 shares, compared to its average volume of 1,522,096. The firm has a market cap of $1.41 billion, a P/E ratio of -3.87 and a beta of 0.84. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The company has a fifty day moving average price of $18.57 and a 200-day moving average price of $18.60.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The firm had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. On average, equities analysts anticipate that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Sandra Calvin sold 54,244 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the sale, the chief accounting officer now owns 54,410 shares of the company's stock, valued at $1,360,250. This trade represents a 49.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP William E. Rote sold 2,437 shares of the business's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the sale, the senior vice president now owns 83,170 shares of the company's stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 188,877 shares of company stock worth $4,147,627 in the last three months. Insiders own 3.75% of the company's stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.